Luigi De Petris

4.4k total citations · 2 hit papers
81 papers, 2.5k citations indexed

About

Luigi De Petris is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Luigi De Petris has authored 81 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Pulmonary and Respiratory Medicine, 44 papers in Oncology and 20 papers in Molecular Biology. Recurrent topics in Luigi De Petris's work include Lung Cancer Treatments and Mutations (51 papers), Lung Cancer Research Studies (31 papers) and Lung Cancer Diagnosis and Treatment (16 papers). Luigi De Petris is often cited by papers focused on Lung Cancer Treatments and Mutations (51 papers), Lung Cancer Research Studies (31 papers) and Lung Cancer Diagnosis and Treatment (16 papers). Luigi De Petris collaborates with scholars based in Sweden, Italy and United States. Luigi De Petris's co-authors include Rolf Lewensohn, Kristina Viktorsson, Filippo de Marinis, Marta Moreno, Lawrence B. Marks, Sara Ramella, Suresh Senan, Tae Hyun Kim, George Rodrigues and Kayoko Tsujino and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Luigi De Petris

79 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis

2013 482 citations David A. Palma, Suresh Senan et al. International Journal of Radiation Oncology*Biology*Physics profile →
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

2015 430 citations Sai‐Hong Ignatius Ou, Jin Seok Ahn et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luigi De Petris Sweden	24	1.6k	1.2k	697	412	368	81	2.5k
J.J. Lafitte France	14	1.5k 0.9×	985 0.8×	612 0.9×	332 0.8×	276 0.8×	22	2.1k
Jin‐Hyoung Kang South Korea	25	1.3k 0.8×	1.3k 1.0×	624 0.9×	418 1.0×	144 0.4×	98	2.2k
Lujun Zhao China	24	1.1k 0.7×	786 0.6×	427 0.6×	242 0.6×	652 1.8×	162	2.1k
Joseph Bucci Australia	27	1.0k 0.7×	663 0.5×	1.2k 1.7×	748 1.8×	382 1.0×	106	2.8k
Saiama N. Waqar United States	29	1.9k 1.2×	1.7k 1.4×	654 0.9×	551 1.3×	292 0.8×	143	2.9k
Panos Fidias United States	25	1.8k 1.2×	1.7k 1.4×	925 1.3×	276 0.7×	269 0.7×	58	3.0k
Corey Speers United States	23	622 0.4×	818 0.7×	800 1.1×	809 2.0×	273 0.7×	92	2.0k
Ichiro Takata Japan	12	2.7k 1.7×	2.3k 1.8×	795 1.1×	345 0.8×	314 0.9×	50	3.4k
Odd Terje Brustugun Norway	30	1.3k 0.8×	1.4k 1.1×	1.1k 1.5×	680 1.7×	186 0.5×	136	2.9k
Baukelien van Triest Netherlands	25	776 0.5×	1.2k 0.9×	643 0.9×	202 0.5×	363 1.0×	79	2.3k

Countries citing papers authored by Luigi De Petris

Since Specialization

Citations

This map shows the geographic impact of Luigi De Petris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luigi De Petris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luigi De Petris more than expected).

Fields of papers citing papers by Luigi De Petris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luigi De Petris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luigi De Petris. The network helps show where Luigi De Petris may publish in the future.

Co-authorship network of co-authors of Luigi De Petris

This figure shows the co-authorship network connecting the top 25 collaborators of Luigi De Petris. A scholar is included among the top collaborators of Luigi De Petris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luigi De Petris. Luigi De Petris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kokaraki, Georgia, et al.. (2025). NTRK Gene Expression in Non-Small-Cell Lung Cancer. SHILAP Revista de lepidopterología. 5(1). 2–2. 1 indexed citations

Tsakonas, Georgios, Per Hydbring, Kenbugul Jatta, et al.. (2024). Treatment of metastatic ALK-positive non-small cell lung cancer: real-world outcomes in a single center study. Translational Lung Cancer Research. 13(11). 2918–2933. 1 indexed citations

Darwich, Adam S., et al.. (2024). Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study. Clinical and Translational Science. 17(8). e13909–e13909. 2 indexed citations

Brustugun, Odd Terje, et al.. (2022). Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer. Cancers. 14(14). 3430–3430. 6 indexed citations

Alexeyenko, Andrey, Odd Terje Brustugun, Radosveta Gencheva, et al.. (2022). Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients. Translational Lung Cancer Research. 11(10). 2064–2078. 4 indexed citations

Franzén, Bo, Kristina Viktorsson, Vitali Grozman, et al.. (2021). Multiplex immune protein profiling of fine‐needle aspirates from patients with non‐small‐cell lung cancer reveals signatures associated with PD‐L1 expression and tumor stage. Molecular Oncology. 15(11). 2941–2957. 10 indexed citations

Rounis, Konstantinos, et al.. (2021). Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors. European Journal of Cancer. 145. 245–254. 63 indexed citations

Karlsson, Anna, Helena Cirenajwis, Hans Brunnström, et al.. (2019). A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer. Scientific Reports. 9(1). 5207–5207. 15 indexed citations

Grozman, Vitali, et al.. (2018). Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden. Lung Cancer. 120. 75–81. 13 indexed citations

10.

Tsakonas, Georgios, Luigi De Petris, & Simon Ekman. (2017). Management of brain metastasized non-small cell lung cancer (NSCLC) – From local treatment to new systemic therapies. Cancer Treatment Reviews. 54. 122–131. 43 indexed citations

11.

Gréen, Henrik, Ilya Kupershmidt, Daniel Edsgärd, et al.. (2015). Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. Clinical Cancer Research. 22(2). 366–373. 20 indexed citations

12.

Ou, Sai‐Hong Ignatius, Jin Seok Ahn, Luigi De Petris, et al.. (2015). Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study. Journal of Clinical Oncology. 34(7). 661–668. 430 indexed citations breakdown →

13.

Rodrigues, George, Suresh Senan, Cary Oberije, et al.. (2014). Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer Beneficial?: A Multi-institutional Propensity-Score Matched Analysis. International Journal of Radiation Oncology*Biology*Physics. 90(1). S654–S654. 2 indexed citations

14.

Bergman, Per, et al.. (2012). Validation of the 7th TNM classification for non-small cell lung cancer: A retrospective analysis on prognostic implications for operated node-negative cases. Acta Oncologica. 52(6). 1189–1194. 17 indexed citations

15.

Lehtiö, Janne & Luigi De Petris. (2010). Lung cancer proteomics, clinical and technological considerations. Journal of Proteomics. 73(10). 1851–1863. 34 indexed citations

16.

Gridelli, Cesare, Andrea Ardizzoni, Jean‐Yves Douillard, et al.. (2009). Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer. 68(3). 319–331. 57 indexed citations

17.

Petris, Luigi De, Lukas M. Orre, Lena Kanter, et al.. (2008). Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. Lung Cancer. 63(3). 410–417. 51 indexed citations

18.

Gridelli, Cesare, Matti Aapro, Sandro Barni, et al.. (2007). Role of colony stimulating factors (CSFs) in solid tumours: Results of an expert panel. Critical Reviews in Oncology/Hematology. 63(1). 53–64. 20 indexed citations

19.

Marinis, Filippo de, Stefano De Santis, & Luigi De Petris. (2006). Second-line chemotherapy for non-small cell lung cancer. Annals of Oncology. 17. v68–v71. 10 indexed citations

20.

Stagnitti, F, et al.. (2002). [Peritoneal papillary serous carcinoma: clinical report].. PubMed. 23(10). 379–82. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact